74
Participants
Start Date
August 29, 2019
Primary Completion Date
August 30, 2025
Study Completion Date
August 30, 2025
ZW25 (Zanidatamab)
"* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1"
Capecitabine
Administered orally twice daily (PO bid)
Cisplatin
Administered IV
Fluorouracil
Administered IV
Leucovorin
Administered IV
Oxaliplatin
Administered IV
Bevacizumab
Administered IV
Gemcitabine
Administered IV
Memorial Sloan Kettering Cancer Center, New York
Seoul National University Bundang Hospital, Seongnam-si
Fox Chase Cancer Center, Philadelphia
H. Lee Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
Pusan National University, Busan
The Cancer and Hematology Centers, Grand Rapids
University of Chicago, Chicago
Nebraska Methodist Hospital, Omaha
MD Anderson Cancer Center, Houston
USC/Norris Comprehensive Cancer Center, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach
Virginia Mason Medical Center, Seattle
Centro de Investigacion Clinica SAGA, Santiago
Icegclinic Research & Care, Santiago
CECIM Biocinetic, Santiago
Centro Internacional de Estudios Clínicos, Santiago
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Center, Toronto
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY